ROS1 as a 'druggable' receptor tyrosine kinase: Lessons learned from inhibiting the ALK pathway
10.1586/era.12.17
Saved in:
Main Authors: | Ou, S.-H.I., Tan, J., Yen, Y., Soo, R.A. |
---|---|
Other Authors: | CANCER SCIENCE INSTITUTE OF SINGAPORE |
Format: | Review |
Published: |
2014
|
Subjects: | |
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/116889 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Targeting ROS1 with anaplastic lymphoma kinase inhibitors: A promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer
by: Chin, L.P., et al.
Published: (2014) -
THE ROLE OF ROS AND VDAC1 IN PARKIN/PINK1-MEDIATED
MITOPHAGY
by: XIAO BIN
Published: (2014) -
Modelling, control and simulation of a 4-legged robot for obstacle avoidance
by: Cham, Xun Yong
Published: (2024) -
Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis
by: Zhu, Viola W., et al.
Published: (2022) -
A study to investigate the involvement of Nadph Oxidase 5 (NOX5) in resveratrol (RSV) - induced reactive oxygen species (ROS) production in U937 cells
by: BHUVANESHWARI D/O SHUNMUGANATHAN
Published: (2011)